Table IV.

Univariate Cox regression analyses for PFS and OS in patients with metastatic colorectal cancer.

A, PFS
Variable	HR	Lower 95% CI	Upper 95% CI	P-value
Sex (female vs. male)	1.16	0.75	1.79	0.4950
ECOG PS (0 vs. 1 or 2)	1.42	0.89	2.26	0.1340
Age, years (<65 vs. ≥65)	0.91	0.59	1.39	0.6532
Primary tumor location (left vs. right)	0.83	0.52	1.34	0.4615
Liver metastasis (negative vs. positive)	1.53	0.99	2.36	0.0515
Lung metastasis (negative vs. positive)	0.91	0.56	1.47	0.6975
Peritoneal metastasis (negative vs. positive)	1.05	0.68	1.59	0.8289
Lymph node metastasis (negative vs. positive)	2.22	1.40	3.51	0.0006c
Tissue RAS mutation (negative vs. positive)	0.68	0.44	1.05	0.0826
Time from the start of first-line chemotherapy, months (<18 vs. ≥18)	0.65	0.42	1.02	0.0586
Grade 3 or 4 neutropenia within the first cycle of treatment (negative vs. positive)	0.50	0.30	0.84	0.0080b
Treatment regimen (bevacizumab vs. other)	0.78	0.51	1.20	0.2623
B, OS
Variable	HR	Lower 95% CI	Upper 95% CI	P-value
Sex (female vs. male)	1.04	0.62	1.75	0.8573
ECOG PS (0 vs. 1 or 2)	1.83	1.07	3.12	0.0273a
Age, years (<65 vs. ≥65)	0.81	0.47	1.37	0.4292
Primary tumor location (left vs. right)	1.01	0.58	1.77	0.9616
Liver metastasis (negative vs. positive)	1.95	1.15	3.30	0.0126a
Lung metastasis (negative vs. positive)	0.81	0.46	1.42	0.4567
Peritoneal metastasis (negative vs. positive)	1.11	0.66	1.85	0.6868
Lymph node metastasis (negative vs. positive)	1.16	0.70	1.91	0.5673
Tissue RAS mutation (negative vs. positive)	1.13	0.67	1.89	0.6407
Time from the start of first-line chemotherapy, months (<18 vs. ≥18)	0.91	0.54	1.52	0.7077
Grade 3 or 4 neutropenia within the first cycle of treatment (negative vs. positive)	0.70	0.40	1.20	0.1950
Treatment regimen (bevacizumab vs. other)	1.37	0.81	2.33	0.2423

^aP<0.05

^bP<0.01

^cP<0.001. PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; RAS, rat sarcoma viral oncogene homolog.